Core Insights - GE HealthCare (GEHC) reported Q4 2025 adjusted EPS of $1.44, exceeding the Zacks Consensus Estimate of $1.43 by 0.7%, but down 0.7% year over year. GAAP EPS was $1.29, a decline of 17.8% from the previous year [1] - For the full year, adjusted EPS increased by 2.2% to $4.59, while GAAP EPS rose 4.8% to $4.55 [1] Revenue Details - Revenues reached $5.7 billion, reflecting a 7.1% year-over-year increase on a reported basis and 4.8% organically, surpassing the Zacks Consensus Estimate by 1.9%. Total company orders grew 2% year over year organically, with a book-to-bill ratio of 1.06X [2][7] - Full-year revenues increased by 4.8% to $20.6 billion, with organic sales growth of 3.5% [3] Segmental Performance - Imaging segment revenues were $2.55 billion, up 6.6% year over year, while segment EBIT decreased by 12.5% to $264 million [4] - Advanced Visualization Solutions generated $1.53 billion in revenues, a 5.9% increase year over year, with EBIT rising 0.7% to $376 million [4] - Patient Care Solutions revenues fell to $825 million, down 0.3% year over year, with EBIT declining 29.6% to $74 million [5] - Pharmaceutical Diagnostics saw revenues of $790 million, up 22.3% year over year, with EBIT increasing by 10% to $234 million [5] Margins and Financial Position - The net income margin was 10.3%, down 320 basis points from the prior year due to tariffs and product mix, although volume and pricing benefits partially offset this decline [6][7] - At the end of Q4, GEHC had cash, cash equivalents, and investments totaling $4.51 billion, an increase from $4.03 billion in the previous quarter. Total assets rose to $36.91 billion from $36.13 billion sequentially [9] 2026 Guidance - GE HealthCare anticipates organic revenue growth of 3-4% for 2026 and adjusted EPS in the range of $4.95-$5.15, indicating a year-over-year growth of 7.9-12.3%. The Zacks Consensus Estimate for 2026 revenues and EPS is $21.38 billion and $4.94, respectively [10] Strategic Initiatives - The company is focused on inorganic growth through acquisitions, having acquired Nihon Medi-Physics and icometrix in 2025, and is set to acquire Intelerad in the first half of 2026 to enhance its cloud-enabled enterprise imaging capabilities [14] - Continued investment in R&D and new product introductions, including advanced imaging systems and AI-enabled diagnostics, underscores GE HealthCare's commitment to precision care and digital transformation [15]

Core Insights - GE HealthCare (GEHC) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.07, exceeding the Zacks Consensus Estimate of $1.05 by 1.9%, although the EPS declined 6.1% year over year [1][7] - Revenues reached $5.14 billion, reflecting a 6% year-over-year increase on a reported basis and a 4% organic growth, surpassing estimates by 1.4% [2][7] - The company updated its 2025 EPS guidance to a range of $4.51-$4.63, accounting for approximately 45 cents of unfavorable impact from tariffs [9][10] Revenue Details - Total revenues of $5.14 billion were driven by strong performance in the U.S. and EMEA markets, with total company orders increasing 6% organically year over year [2][7] - The revenue growth was supported by the Imaging and Pharmaceutical Diagnostics segments, which offset weaknesses in Patient Care Solutions [7][10] Segmental Performance - Imaging segment revenues totaled $2.35 billion, up 5% year over year, while segment EBIT decreased by 16% to $240 million [3] - Advanced Visualization Solutions generated $1.3 billion in revenues, a 7% increase year over year, with EBIT rising 17% to $271 million [4] - Patient Care Solutions saw revenues of $731 million, down 6% year over year, with EBIT declining 67% to $27 million [3][4] Financial Position - GEHC ended the third quarter with cash, cash equivalents, and investments totaling $4.03 billion, an increase from $3.76 billion in the previous quarter [6] - Total assets rose to $36.13 billion from $35.5 billion sequentially [8] Margins and Cash Flow - The net income margin was 8.7%, down 100 basis points from the prior year, influenced by tariffs but partially offset by volume and price benefits [5] - Cumulative cash flow from operating activities was $937 million, down from $1.04 billion a year ago [5] Strategic Outlook - Continued investment in R&D and new product introductions, including advanced imaging systems and AI-enabled diagnostics, reflects GE HealthCare's commitment to innovation [11] - The company is focused on operational efficiency and disciplined pricing to mitigate cost pressures, indicating strong customer confidence [12]

Core Insights - GE HealthCare (GEHC) plans to acquire icometrix, a Belgium-based company specializing in AI-powered brain imaging solutions, to enhance its precision care strategy and expand its neurological care portfolio, particularly in managing complex neurological conditions like Alzheimer's disease [1][2][5] Acquisition Details - The acquisition aims to strengthen GEHC's position in precision care, especially in neurology, by integrating icometrix's AI insights with GEHC's advanced imaging technologies [2][5] - Financial terms of the deal are undisclosed, and GE HealthCare intends to fund the acquisition with cash on hand, pending regulatory approvals [2] - icometrix's icobrain platform provides quantitative analysis of brain MRI scans for various disorders, including Alzheimer's, and features the first FDA-cleared CAD solution for detecting side effects of amyloid-targeting therapies [7][8] Market Context - The number of adults living with Alzheimer's is projected to double by 2050, increasing the demand for advanced imaging and decision-support tools due to the need for frequent neurological MRI exams [9] - GEHC's stock has lost 0.6% this year, while the industry has gained 6.6%, and the S&P 500 Index has increased by 12.7% during the same period [3] Strategic Implications - The acquisition is viewed as a long-term growth catalyst for GEHC, reinforcing its position in the expanding neurology and Alzheimer's care markets [5] - The integration of icometrix's solutions is expected to streamline workflows and enhance the efficiency of handling growing scan volumes while maintaining high care standards [8]

Table of Contents As filed with the U.S. Securities and Exchange Commission on June 5, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GE HealthCare Technologies Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 3844 88-2515116 (Primary Standard Industrial Classification Code Number) 500 W. Monroe Street Chicago ...